TRAW · XBRL financial data
Traws Pharma financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TRAW's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 231 | 226 | 226 | 226 | 226 | 2,790 |
| Research and development | 16,898 | 7,297 | 11,406 | 11,430 | — | — |
| General and administrative | 8,326 | 9,425 | 8,447 | 9,094 | 12,289 | 8,522 |
| Total operating expenses | 25,224 | 16,722 | 19,853 | 20,524 | 142,600 | 20,665 |
| Operating income (loss) | (24,993) | (16,496) | (19,627) | (20,298) | (142,374) | (17,875) |
| Interest income | — | — | 651 | 1,391 | 510 | 455 |
| Other income (expense) | 48 | 12 | 663 | 1,350 | 289 | 478 |
| Income tax expense (benefit) | 4 | — | — | — | — | — |
| Net income (loss) | (25,157) | (16,163) | (18,964) | (18,948) | (166,523) | 9,170 |
| Earnings per share, basic‡ USD per share | (54.25) | (24.00) | (22.75) | (22.50) | (35.21) | 0.83 |
| Earnings per share, diluted‡ USD per share | (54.25) | (24.00) | (22.75) | (22.50) | (35.21) | 0.82 |
| Weighted average shares, basic‡ thousands of shares | 464 | 673 | 836 | 840 | 1,553 | 8,228 |
| Weighted average shares, diluted‡ thousands of shares | 464 | 673 | 836 | 840 | 1,553 | 8,376 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (September 2024); filings made before it reported them unadjusted.
- † Share count changed about 1/11 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (TRAW's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 19,025 | 55,070 | 38,522 | 20,559 | 21,338 | 3,820 |
| Prepaid and other current assets | 722 | 332 | 561 | 1,821 | 1,848 | 365 |
| Total current assets | 19,784 | 55,430 | 39,347 | 22,660 | 24,951 | 7,979 |
| Property and equipment, net | 52 | 38 | 24 | 22 | 10 | 7 |
| Total assets | 19,986 | 55,478 | 39,372 | 22,683 | 24,962 | 10,617 |
| Accounts payable | 4,833 | 2,757 | 3,860 | 5,619 | 8,186 | 5,653 |
| Accrued liabilities | 4,962 | 3,132 | 3,960 | 3,375 | 3,121 | 5,493 |
| Total current liabilities | 10,021 | 6,115 | 8,046 | 9,220 | 11,533 | 11,146 |
| Total liabilities | 13,811 | 9,358 | 11,063 | 12,011 | 56,592 | 11,246 |
| Accumulated deficit | (428,556) | (444,719) | (463,683) | (482,631) | (649,154) | (639,984) |
| Total liabilities and equity | 19,986 | 55,478 | 39,372 | 22,683 | 24,962 | 10,617 |
| Common shares outstanding (cover page)‡ thousands of shares | 9,464 | 836 | 839 | 842 | 5,074 | 10,157 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (September 2024); filings made before it reported them unadjusted.
- † Share count changed about 1/11 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (TRAW's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (25,157) | (16,163) | (18,964) | (18,948) | (166,523) | 9,170 |
| Stock-based compensation | 369 | 576 | 1,172 | 1,301 | 1,390 | 728 |
| Depreciation and amortization | 13 | 14 | 14 | 16 | 12 | 61 |
| Net cash from operating activities | (23,075) | (19,487) | (16,294) | (17,932) | (29,792) | (18,185) |
| Purchases of property and equipment | 15 | — | — | 14 | — | — |
| Net cash from investing activities | (15) | — | — | (14) | (3,648) | (2,585) |
| Proceeds from issuing common stock | 9,062 | 55,041 | — | — | — | 5,582 |
| Net cash from financing activities | 19,357 | 55,560 | — | — | 33,976 | 3,204 |
| Net change in cash | (3,701) | 36,045 | (16,313) | (17,936) | 517 | (17,518) |
- † Share count changed about 1/11 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Alaunos Therapeutics | 124 | 0 | (300)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4,198 | not reported | (5,033)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.